全球维生素 D 治疗市场 - 2022-2029
市场调查报告书
商品编码
1143415

全球维生素 D 治疗市场 - 2022-2029

Global Vitamin D Therapy Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计维生素 D 治疗市场在预测期间(2022-2029 年)将以 12.2% 的复合年增长率增长。

维生素 D 是一种脂溶性维生素,身体会因皮肤暴露在阳光下而产生。它也天然存在于一些食物中,如鱼、鱼肝油、蛋黄、强化乳製品和谷物产品。维生素 D 对支持体内钙代谢至关重要。通过从食物和补充剂中吸收钙来支持维持健康的骨细胞。维生素 D 还支持肌肉健康、参与免疫系统、帮助细胞生长、调节血压并支持心血管健康。血清维生素 D 水平低于 20 ng/mL 的人有维生素 D 缺乏的风险。血清维生素 D 水平低于 12 ng/mL 表明维生素 D 缺乏。缺乏维生素 D 会导致糖尿病、癌症、佝偻病、骨质疏鬆症、肾病等。

市场动态

市场增长的驱动因素是人们对维生素 D 缺乏症的认识不断提高、人口老龄化加剧、饮食不均衡、肥胖、久坐不动的生活方式等。

预计全球维生素 D 缺乏症的日益流行将推动市场增长。

维生素 D 缺乏症与多种慢性和传染病有关。根据文献,这种缺陷的流行可能因地域而异。包括沙特阿拉伯在内的中东和北非地区的维生素 D 不足率相对较高,所有年龄组的维生素 D 不足率为 82%。全球对维生素 D 缺乏症的认识不断提高是影响市场的主要因素。此外,美国国立卫生研究院 (NIH) 膳食补充剂办公室 (ODS) 赞助并资助了许多研究,以促进对维生素 D 对健康价值的科学认识。

此外,增加研发以扩大维生素 D 治疗的使用预计将在未来推动市场。美国食品和药物管理局最近批准增加可作为可选成分添加到牛奶中的维生素 D 的含量,并且还添加了许多其他牛奶替代品,包括大豆、杏仁和椰子饮料,以及可食用植物基饮料酸奶替代品。批准在可食用植物製成的饮料中添加维生素 D。因此,从上述陈述来看,预计它将成为预测期内市场的驱动力。

限制

全球品牌的存在和可用性、来自本地和国家品牌的激烈或激烈竞争所带来的挑战是预测期内可能阻碍市场发展的方面。

行业分析

维生素 D 治疗市场根据各种行业因素(包括未满足的需求、定价分析、供应链分析和监管分析)对市场进行深入分析。

细分分析

在维生素 D 治疗市场中,预计口服部分将占据最大的市场份额。

2021 年,口腔领域将占据最大的市场份额。该部门受益于给药方便、药代动力学和药效学性能改善、毒性风险降低、患者耐受性提高和对口服途径的偏好等原因。口服途径是最常见和批准的给药途径。最简单、最方便、最安全的方式。它是无痛的,患者可以作为片剂服用或与食物混合服用。因此,从上述描述来看,市场细分在预测期内占据了最大的市场份额。

区域分析

预计北美将占据全球维生素 D 治疗市场的最大市场份额。

北美将在 2021 年占销售额的最高份额。维生素 D 缺乏症和骨质疏鬆症等慢性病病例不断增加、公众意识、政府支持政策、高额报销等等。据 IOF 称,骨质疏鬆症和低骨量对大约 4400 万 50 岁及以上的美国女性和男性构成重大的公共健康威胁。此外,雅培在 2021 年被评为维生素 D 缺乏症治疗顶□□级品牌,在研发方面投入最多,并以可承受的成本提供尖端治疗。这增加了该地区对维生素 D 治疗的需求。因此,从上述描述来看,北美地区在预测期内占据了最大的市场份额。

竞争格局

维生素 D 治疗市场的主要关键参与者是:雅培、赛诺菲、葛兰素史克、辉瑞公司、默克公司、Torrent Pharmaceuticals、诺华国际公司、Alkem 实验室、Sun Pharmaceutical Industries 和 Cadila Healthcare Ltd. (Abbott)。

雅培实验室

概述

Abbott Laboratories 是一家美国跨国医疗器械和医疗保健公司,拥有广泛而多元化的医疗保健产品发现、开发、製造和营销组合。 2013 年,我们将研发製药业务拆分为 AbbVie。我们通过以下部门获利:药物、营养学、诊断学、心血管和神经调节剂等。医疗器械、诊断和营养领域的知名产品包括 Pedialyte、Similac、Ensure、Glucerna、ZonePerfect、FreeStyle Libre、i-STAT 和 MitraClip。 190,000 名员工为 160 多个国家的人们提供服务。

产品组合

Avocal: 预防钙、维生素 D、维生素 C 和维生素 B6 缺乏症,通过减少饮食中维生素 C、维生素 D 和维生素 B6 的摄入量来治疗缺乏症。

本报告提供了超过 45 个 市场数据表、超过 40 个图表和 180 页有关全球维生素 D 治疗市场的信息。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按管理途径划分的市场细分
  • 按应用划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分
  • DataM CLO 场景

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 提高对维生素 D 缺乏症的认识
      • 老年人口增加
      • 饮食不均衡
      • 肥胖
      • 久坐不动的生活方式
    • 约束因素
      • 普通消费者缺乏认识
      • 与外部摄入补充剂相关的副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 流行病学

第 6 章给药途径

  • 口语
  • 肠胃外
  • 局部给药

第 7 章按应用程序

  • 骨质疏鬆症
  • 佝偻病
  • 皮肤病
  • 肌肉无力
  • 自身免疫性疾病
  • 其他

第 8 章按销售渠道

  • 医院药房
  • 零售药房
  • 在线药店

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 竞争性维生素 D 治疗策略分析
  • 比较产品组合分析
  • 市场情况/份额分析
  • 併购分析

第 11 章公司简介

  • 雅培
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Sanofi
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Torrent Pharmaceuticals Ltd.
  • Novartis International AG
  • Alkem Laboratories
  • Sun Pharmaceutical Industries
  • Cadila Healthcare Ltd.

第12章 重要考察

第13章 DataM

简介目录
Product Code: DMPH1890

Market Overview

Vitamin D Therapy Market is expected to grow at a CAGR of 12.2% during the forecasting period (2022-2029).

Vitamin D is a fat-soluble vitamin produced by the body in response to skin being exposed to sunlight. It also occurs naturally in a few foods such as fish, fish liver oils, egg yolks, and fortified dairy and grain products. Vitamin D is essential for supporting calcium metabolism in the body. It helps the body absorb calcium from food and supplements to support the maintenance of healthy bone cells. Vitamin D also supports muscle health, plays a role in the immune system, aids cell growth, regulates blood pressure, and supports cardiovascular health. People with less than 20 ng/mL serum vitamin D levels are at risk for vitamin D deficiency. Serum levels below 12 ng/mL indicate a vitamin D deficiency. Vitamin D deficiency can cause diabetes, cancer, rickets, osteoporosis, and kidney diseases.

Market Dynamics

The market growth is driven by growing awareness about vitamin D deficiency, a rise in the geriatric population, an imbalanced diet, obesity, and a sedentary lifestyle.

Increasing vitamin D deficiencies worldwide is expected to drive market growth.

Vitamin D deficiency is linked to various chronic and infectious diseases. According to the literature, the prevalence of this deficit can vary geographically. The Middle East and North African region, which includes Saudi Arabia, has a comparatively high rate of vitamin D insufficiency, with 82% of all age groups deficient. Increased global awareness of vitamin D deficiency is a major factor influencing the market. Moreover, the National Institutes of Health (NIH) Office of Dietary Supplements (ODS) sponsored and funded a number of studies to improve scientific understanding of vitamin D's value to health.

Furthermore, increased R&D to expand the uses of vitamin D treatment is projected to help the market gain traction in the future years. The US Food and Drug Administration recently approved an increase in the amount of vitamin D that can be added as an optional ingredient to milk, as well as the addition of vitamin D to beverages made from edible plants that are intended to be milk substitutes, such as soy, almond, and coconut beverages, and edible plant-based yogurt alternatives. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The presence and availability of global brands, as well as the challenges they encounter due to big or scant competition from local and domestic brands, are aspects the market is likely to be hampered by during the forecast period.

Industry Analysis

The vitamin D therapy market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Oral segment is expected to hold the largest market share in the vitamin D therapy market.

The oral segment accounted for the largest market share in 2021. The segment benefited because of the convenience of administration, increased pharmacokinetic and pharmacodynamic performance, lower toxicity risk, improved patient tolerance, and a preference for the oral route. The oral route is the most common and approved route for pharmaceutical administration. It is the simplest, most convenient, and most secure method. It is not painful, and the patient can take it as tablets or mix it with food. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global vitamin D therapy market.

North America accounted for the highest revenue share in 2021. Rise in cases of vitamin D deficiency and other chronic diseases such as osteoporosis, public awareness, supportive government policies, and high reimbursement. According to IOF, osteoporosis and low bone mass are significant public health threats for almost 44 million U.S. women and men aged 50 and older. Moreover, Abbot was named the leading brand in Vitamin D insufficiency treatment in 2021, with the most money invested in research and development and providing cutting-edge treatments at accessible costs. Therefore, it has increased the demand for Vitamin D therapy in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the vitamin D therapy market are: Abbott, Sanofi, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc., Torrent Pharmaceuticals, Novartis International AG, Alkem Laboratories, Sun Pharmaceutical Industries, and Cadila Healthcare Ltd.

Abbott Laboratories:

Overview:

Abbott Laboratories is an American multinational medical device and healthcare company that explores, develops, manufactures, and sells a broad and diversified line of healthcare products. It split off its research-based pharmaceuticals business into AbbVie in 2013. It benefits through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Others. Its well-known products across the medical devices, diagnostics, and nutrition divisions are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. One hundred nine thousand colleagues serve people in more than 160 countries.

Product Portfolio:

ABOCAL: To help prevent deficiencies of Calcium, vitamin D, vitamin C and vitamin B6, for the treatment of deficiency state resulting from reduced intake of vitamin C, vitamin D and vitamin B6 in the diet.

The global vitamin D therapy market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Route of Administration
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region
  • 3.5. DataM CLO Scenario

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing awareness about vitamin D deficiency
      • 4.1.1.2. Rise in geriatric population
      • 4.1.1.3. Imbalanced diet
      • 4.1.1.4. Obesity
      • 4.1.1.5. Sedentary life style
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of awareness among the common population
      • 4.1.2.2. Side effects associated with external intake of supplements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology

6. By Route of Administration

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 6.3. Market Attractiveness Index, By Route of Administration
  • 6.4. Oral
    • 6.4.1. Introduction
    • 6.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.5. Parenteral
  • 6.6. Topical

7. By Application

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 7.3. Market Attractiveness Index, By Application
  • 7.4. Osteoporosis
    • 7.4.1. Introduction
    • 7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.5. Rickets
  • 7.6. Skin Diseases
  • 7.7. Muscle Weakness
  • 7.8. Autoimmune Disorders
  • 7.9. Others

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3. Market Attractiveness Index, By Distribution Channel
  • 8.4. Hospital pharmacies
    • 8.4.1. Introduction
    • 8.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.5. Retail pharmacies
  • 8.6. Online pharmacies

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Italy
      • 9.5.6.5. Spain
      • 9.5.6.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia-Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Competitor Vitamin D Therapy Strategy Analysis
  • 10.3. Comparative Product Portfolio Analysis
  • 10.4. Market Positioning/Share Analysis
  • 10.5. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Abbott *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sanofi
  • 11.3. GlaxoSmithKline plc
  • 11.4. Pfizer Inc.
  • 11.5. Merck & Co., Inc.
  • 11.6. Torrent Pharmaceuticals Ltd.
  • 11.7. Novartis International AG
  • 11.8. Alkem Laboratories
  • 11.9. Sun Pharmaceutical Industries
  • 11.10. Cadila Healthcare Ltd.

12. Premium Insights

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us